Pirtobrutinib (formerly LOXO-305 and LY-3527727) is a novel, highly selective and non-covalent next generation BTK (Bruton's tyrosine kinase) inhibitor which inhibits diverse BTK C481 substitution mutations. Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and intolerance. Pirtobrutinib was safe and active in multiple B-cell malignancies, including patients previously treated with covalent BTK inhibitors. Pirtobrutinib might address a growing unmet need for alternative therapies for these patients.

纯度：≥98%

CAS：2101700-15-4